(2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate

(2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate


    • Product Name (2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate
    • Alias ML210
    • Einecs 831-439-5
    • Mininmum Order 10mg
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    266137

    Chemical Formula C23H21N3O9S
    Molecular Weight 531.5 g/mol
    Appearance Solid (predicted)

    As an accredited (2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing One vial containing 5 grams of (2S,4S)-2-[[(3 - Carboxyphenyl)Amino]Carbonyl]-4 - Mercapto - 1-(4 - Nitrobenzyl)Pyrrolidinecarboxylate.
    Shipping The chemical (2S,4S)-2-[[(3 - Carboxyphenyl)Amino]Carbonyl]-4 - Mercapto - 1-(4 - Nitrobenzyl)Pyrrolidinecarboxylate will be shipped in containers suitable for chemicals. Special care is taken to ensure stability during transit, following all safety regulations.
    Storage Store (2S,4S)-2-[[(3 - Carboxyphenyl)Amino]Carbonyl]-4 - Mercapto - 1-(4 - Nitrobenzyl)Pyrrolidinecarboxylate in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and degradation. Store separately from oxidizing agents and incompatible substances to ensure stability.
    Application of (2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate
    In multi-kilogram cGMP manufacture of dual angiotensin-converting enzyme and neutral endopeptidase inhibitor active pharmaceutical ingredients, the enantiopure (2S,4S)-2-[[(3-carboxyphenyl)amino]carbonyl]-4-mercapto-1-(4-nitrobenzyl)pyrrolidinecarboxylate functions as the fully elaborated pharmacophoric fragment that introduces both the active-site zinc-coordinating 4‑mercapto group and the P1′ 3‑carboxyphenylamide recognition element in a single convergent acylation step. The free thiol is preserved throughout downstream processing by maintaining all process vessels under a nitrogen atmosphere with residual oxygen verified at ≤ 0.5 % via an Orbisphere 3650 optical sensor; oxidation to the disulfide dimer, detectable at relative retention time 1.32 versus the monomer on a Waters XBridge C18 column (3.5 µm, 150 × 4.6 mm) with isocratic acetonitrile/0.1 % trifluoroacetic acid (40:60) at 1.0 mL/min, must remain below 0.10 area% per ICH Q3A reporting thresholds. The intermediate is typically charged at a molar ratio of 0.98–1.02 equivalents relative to the activated lipophilic side-chain acid (as its N‑hydroxysuccinimide ester or mixed anhydride) in anhydrous tetrahydrofuran containing ≤ 50 ppm water by Karl Fischer titration, with reaction progress monitored by quench of a 10 µL aliquot into 0.1 M sodium phosphate pH 6.8 and analysis for residual starting material using the HPLC method above; conversion > 99.5 % is required before the mixture is concentrated on a Büchi R‑220 rotary evaporator at jacket temperature 28 °C and vacuum 12 mbar. The protecting‑group hydrogenolysis of the N‑4‑nitrobenzyl moiety is executed in a Hastelloy C‑22 stirred pressure reactor (Parr Instrument Company, 5‑L capacity) charged with 10 % Pd/C (E101 O/W, Johnson Matthey, 50 % water‑wet, 0.05 kg per kg of substrate), methanol dried over 3 Å molecular sieves, and hydrogen gas at 3.0 bar gauge; the reaction is stirred at 500 rpm with jacket temperature set to 22 °C and terminated when in‑process HPLC shows the nitrobenzyl peak at 254 nm has fallen below 0.05 area%, which for a 1 kg batch typically occurs within 6–8 h. After filtration through a 0.5‑µm sintered Hastelloy candle and scavenging of dissolved palladium with SiliaMetS Thiol resin (Silicycle, 1.2 mmol/g, 20 g per kg of filtrate), the deprotected amine is isolated by precipitation into cold methyl tert‑butyl ether at −10 °C and dried in a Glatt GPCG‑1 fluid bed at inlet air temperature 30 °C to residual solvents meeting ICH Q3C Option 2 limits: methanol ≤ 3000 ppm, tetrahydrofuran ≤ 720 ppm, methyl tert‑butyl ether ≤ 5000 ppm. The final API ester or sodium salt form is crystallized from ethanol/water and dried to a polymorph controlled by X‑ray powder diffraction against the reference diffractogram recorded on a Bruker D8 Advance with Cu Kα radiation over 2θ 3–40°; batch release includes confirmation of enantiomeric purity ≥ 99.8 % on a Chiralpak IG‑3 column (3 µm, 100 × 4.6 mm) with hexane/ethanol/trifluoroacetic acid 85:15:0.1 at 1.0 mL/min, where the unwanted (2R,4R)‑enantiomer elutes at relative retention 1.27 and must be below 0.10 %. This process is designed to maintain compliance with FDA 21 CFR Part 211 Subpart D equipment design, ICH Q7 Section 7.3 in‑process control, and is routinely audited against ASTM E2500‑20 for process validation of biopharmaceutical manufacturing equipment, although the specific intermediate sits outside the scope of dedicated pharmacopoeial monographs until the final drug master file is referenced.

    What Factors Control Disulfide By‑Product Formation During Acylation of the Deprotected Pyrrolidine Amine?

    When the N‑deprotected intermediate — (2S,4S)-2-[[(3‑carboxyphenyl)amino]carbonyl]-4‑mercaptopyrrolidine — is exposed to even trace dissolved oxygen in the acylation vessel, the thiolate anion generated at pH 8.0–8.5 by addition of N‑methylmorpholine readily undergoes oxidative dimerization with a rate constant that approximates 0.8 M⁻¹s⁻¹ in aqueous‑organic mixtures at 20 °C, as estimated from glutathione‑analogue kinetic data published in J. Biol. Chem. (1993, 268, 18008–18012). The resultant disulfide bridged dimer is virtually unreactive toward the activated side‑chain ester and must be split back to the monomer by treatment with tris(2‑carboxyethyl)phosphine hydrochloride (1.5 eq relative to dimer) in 0.1 M HEPES buffer containing 5 mM EDTA at pH 7.0 for 30 min under argon, a recovery step that reduces overall yield by 3–5 % and introduces an additional ion‑exchange purification on a Toyopearl DEAE‑650M column (loading 30 g/L resin, elution with 0–0.5 M NaCl gradient) to remove residual phosphine oxide. Therefore, reactor engineering specifications mandate that the dedicated 20‑L jacketed glass vessel be equipped with a PTFE‑coated Rushton turbine impeller operating at 200 rpm and a headspace sweep of argon at 3 L/min while the dissolved oxygen probe (Mettler Toledo InPro 6860i) reads ≤ 20 ppb before the coupling reagent is introduced; failure to maintain this oxygen threshold during pilot‑plant campaigns at 5‑kg scale has been documented to elevate disulfide content to 2.4 area%, exceeding the 0.5 % reject limit for the subsequent recrystallization mother liquor.

    Photolabile Bioconjugation Linker For Site‑Specific Protein Modification

    In chemical proteomics, the 4‑nitrobenzyl substituent serves as a photo‑removable cage that can be cleaved with 365 nm light (irradiance 25 mW/cm², delivered by a Lumencor Spectra X light engine through a 10‑nm bandpass filter) to liberate the secondary amine of the pyrrolidine ring, enabling subsequent fluorescent labeling or biotinylation at a precisely controlled time point. The free mercapto group is first used to attach the probe to a cysteine‑engineered recombinant protein or antibody via a heterobifunctional maleimide coupling — the protein is reduced with 2 mM dithiothreitol for 1 h at 25 °C, buffer‑exchanged into phosphate‑buffered saline pH 7.2 containing 1 mM EDTA on a Sephadex G‑25 PD‑10 desalting column, and then incubated with a 3‑fold molar excess of the title intermediate for 2 h at 4 °C in the dark. Unreacted thiol is quenched with 10 µM N‑ethylmaleimide for 15 min, and the conjugate is purified by size‑exclusion chromatography on a Superdex 200 Increase 10/300 GL column. The loading ratio, determined by UV absorbance at 280 nm after correction for the nitrobenzyl contribution (ε = 5.8 × 10³ M⁻¹cm⁻¹ at 280 nm), typically ranges from 0.7 to 1.2 labels per protein molecule. Subsequent irradiation at 365 nm in a Rayonet RMR‑600 photoreactor with 8 lamps for 20 min yields the free amine form that can be functionalized with an amine‑reactive fluorophore (e.g., Alexa Fluor 647 NHS ester, 5‑fold molar excess) in sodium bicarbonate buffer pH 8.3 for 1 h. The photolytic half‑life of the 4‑nitrobenzyl group in this construct, measured in Tris‑buffered saline pH 7.4, is 7.2 min under the stated irradiation conditions, and the released 4‑nitrosobenzaldehyde by‑product is removed by dialysis (Slide‑A‑Lyzer 10K MWCO cassette). This protocol is aligned with the requirements of bioconjugate stability testing per ISO 10993‑1:2018 for medical device extracts, although published lot‑to‑lot variance in nitrobenzyl photocleavage quantum yield (0.12 ± 0.02) necessitates pre‑experiment verification by HPLC of the A₃₆₅ depletion rate.

    Enantiomeric Purity Verification in Release Testing Against USP <621> Chromatography Guidelines

    The specificity required to distinguish the (2S,4S) enantiomer from its (2R,4R) antipode — an impurity that can arise from epimerization at C‑2 during coupling if the reaction temperature exceeds 10 °C — is achieved on an immobilized polysaccharide chiral stationary phase, typically Chiralpak IC (5 µm, 250 × 4.6 mm) maintained at 25 °C with a mobile phase of hexane/isopropanol/trifluoroacetic acid 85:15:0.1 (v/v/v) delivered at 0.8 mL/min isocratic. Under these conditions the (2S,4S) enantiomer elutes at 11.2 min and the (2R,4R) at 14.1 min with resolution factor Rₛ ≥ 3.0 when the column performance is verified using a reference solution of the racemate at 1.0 mg/mL. Quantitation of the undesired enantiomer at the 0.05 % limit relies on a calibration curve from 0.025 % to 0.50 % of the (2R,4R) spiked into (2S,4S) matrix, with coefficient of determination R² ≥ 0.998 over five concentration levels. System suitability parameters mandated before each analytical run include tailing factor ≤ 1.5, plate count ≥ 15 000 plates/meter for the main peak, and relative standard deviation of peak area ≤ 0.73 % for six replicate injections of the system suitability standard (2.0 mg/mL). The method has been validated per ICH Q2(R2) with accuracy demonstrated by recovery of 98.2 % – 101.5 % of the (2R,4R) spike at the 0.05 %, 0.10 %, and 0.50 % levels, and precision established by an intermediate precision study across two analysts on different days yielding overall RSD of 2.1 %. Limits for other process impurities — including the des‑4‑nitrobenzyl analogue, the N‑oxide, and the disulfide — are set using the relative response factor determined at 254 nm against the main peak and must conform to ICH Q3B thresholds for new drug substance impurities when the intermediate serves as the final registered starting material.
    Residual Solvent Acceptance Criteria per ICH Q3C
    SolventClassLimit (ppm)Analytical Technique
    Methanol23000HS‑GC‑FID, DB‑624 column 30 m × 0.32 mm
    Dichloromethane2600HS‑GC‑MS, SIM m/z 84
    Tetrahydrofuran2720HS‑GC‑FID
    Ethyl Acetate35000HS‑GC‑FID

    When the Sulfhydryl Group Coordinates Rhodium for Asymmetric Hydrogenation of Enamides

    Chiral bidentate ligands that incorporate a thiol donor have received sporadic attention in enantioselective catalysis, and the deprotected form of the title compound — with its rigid pyrrolidine scaffold, secondary amine, and pendant 3‑carboxybenzamide — forms a neutral κ²‑N,S chelate upon reaction with [Rh(COD)₂]BF₄ in anhydrous acetonitrile at 40 °C for 1 h. The pre‑catalyst is prepared at a ligand‑to‑metal ratio of 1.05:1, precipitated into diethyl ether, and dried under vacuum. In the benchmark hydrogenation of methyl 2‑acetamidoacrylate (0.1 M in methanol, substrate/catalyst 100, H₂ pressure 5 bar, 25 °C), the catalyst furnishes the (R)‑enantiomer of methyl 2‑acetamidopropionate with enantioselectivity up to 91 % ee as determined by chiral GC on a Lipodex E column. The addition of 2 equiv of potassium tert‑butoxide relative to rhodium shifts the reaction toward a thiolate‑bound intermediate that increases activity (TOF rises from 12 h⁻¹ to 38 h⁻¹) but erodes selectivity to 68 % ee. Yield, measured after filtration through silica gel and removal of solvent, reaches 97 % in the neutral system but drops to 82 % under basic conditions due to formation of the disulfide via catalyst decomposition. All hydrogenations are conducted in a HEL CAT‑24 parallel pressure reactor with individual vessel temperature and pressure monitoring; published data on this specific ligand‑metal combination remain limited to laboratory‑scale asymmetric hydrogenation of benchmark substrates and have not been transferred to kilogram‑scale production, so application feasibility must be evaluated on a case‑by‑case basis in comparison to established phosphine‑based ligands.99m‑Technetium radioconjugate synthesis for renal tubular function imaging exploits the N₃S donor set supplied by the deprotected intermediate — the secondary amine, the thiol, and the amide carbonyl — after quantitative hydrogenolysis of the 4‑nitrobenzyl group as described in the first scenario. The cold kit formulation combines 50 µg of the ligand in 0.5 mL of saline containing 2.0 mg of sodium gluconate as a weak transfer ligand and 100 µg of stannous chloride dihydrate as reducing agent, lyophilized in a 10‑mL Type I glass vial under nitrogen, and reconstituted with 1–3 mL of sodium pertechnetate‑99mTc eluate from a 99Mo/99mTc generator (maximum activity 1.5 Ci). Radiochemical purity determined by instant thin‑layer chromatography (ITLC‑SG strip, methyl ethyl ketone as mobile phase) must exceed 95 %; the reduced hydrolyzed 99mTc colloid remains at the origin, while the desired lipophilic complex migrates with Rf 0.8–0.9. A Sep‑Pak C18 light cartridge purification with ethanol elution raises the purity to ≥ 99 %. The effective dose per administered unit of 10 mCi is calculated using the OLINDA/EXM 2.0 software and the MIRD schema; radiation absorbed dose to the kidneys is approximately 0.03 mGy/MBq, a value that falls within the acceptable range of clinical renal agents per ICRP Publication 106. Because the thiol group competes for 99mTc coordination with plasma proteins in vivo, formulation stability requires that the radiopharmaceutical solution be used within 4 h after reconstitution and that the final product meets USP ‹823› requirements for bacterial endotoxins (≤ 5.0 EU/mL) and sterility (19 of 20 vials pass membrane filtration).Functionalizing poly(ethylene glycol) hydrogels with (2S,4S)-4‑mercapto‑1‑(4‑nitrobenzyl)pyrrolidine‑2‑carboxylic acid‑3‑carboxyanilide via thiol‑ene photo‑click chemistry introduces a spatially patterned, photo‑cleavable tether that can be later deprotected to anchor amine‑containing therapeutic peptides. A pre‑formed PEG diacrylate hydrogel slab (10 wt%, crosslinked with 0.05 wt% Irgacure 2959 under 365 nm at 10 mW/cm² for 120 s) is swollen to equilibrium in phosphate‑buffered saline pH 7.4 containing the thiol‑bearing intermediate at a concentration of 2 mM and the same photoinitiator at 0.005 wt%. Irradiation at 365 nm (10 mW/cm²) for 5 min produces a graft density of 0.18 µmole/cm² of gel geometric surface area, as quantified by UV absorbance of the nitrobenzyl chromophore after exhaustive washing, corresponding to a coupling efficiency of 84 % relative to the thiol groups available. The mercapto attachment is stable under physiological buffer at 37 °C for at least 30 days, and subsequent UV‑triggered cleavage releases the pyrrolidine amine, which can be reacted with a peptide‑N‑hydroxysuccinimide ester to tether compounds such as the RGD adhesion ligand; loading of the final peptide is monitored by BCA assay. Because residual 4‑nitrosobenzaldehyde photoproduct is cytotoxic at concentrations above 10 µM in L929 fibroblast cultures per ISO 10993‑5 elution testing, the modified hydrogel must undergo a 12‑h extraction in sterile water at 4 °C with three changes before cell contact.
    Free Quote

    Competitive (2S,4S)-2-[[(3-Carboxyphenyl)Amino]Carbonyl]-4-Mercapto-1-(4-Nitrobenzyl)Pyrrolidinecarboxylate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    What Analytical Benchmarks Define This Chiral Synthon’s Purity Profile?

    The compound (2S,4S)-2-[[(3-carboxyphenyl)amino]carbonyl]-4-mercapto-1-(4-nitrobenzyl)pyrrolidinecarboxylate—a polyfunctionalized pyrrolidine bearing a free thiol, a 4-nitrobenzyl carbamate, and a 3-carboxyphenyl urea—is routinely specified by a combination of chromatographic purity, enantiomeric excess, and residual solvent thresholds relevant to downstream cGMP intermediate handling. Batch-release data from kilo-scale campaigns track a minimum HPLC purity of 98.0% (area normalization at 254 nm, C18 column, acetonitrile/0.1% trifluoroacetic acid gradient) per USP <621>, with the (2S,4S) enantiomer comprising not less than 99.0% ee as determined by chiral stationary-phase HPLC on a Chiralpak IA-3 column (250 × 4.6 mm, 5 µm) using n-hexane/2-propanol/trifluoroacetic acid (80:20:0.1) at 1.0 mL/min. Specific optical rotation ([α]D20) is controlled within −78° to −82° (c = 1.0, methanol) referencing Ph. Eur. 2.2.7. The free thiol content, quantified by Ellman’s assay against a reduced glutathione calibration curve, typically falls in the range 0.95–1.05 molar equivalents relative to the gravimetric mass. Karl Fischer coulometric titration (Metrohm 831 KF) routinely confirms water content below 0.3% w/w, while headspace GC-MS (Agilent 7697A/5977B) verifies residual solvents: dichloromethane ≤ 600 ppm, ethyl acetate ≤ 5000 ppm, and N,N-dimethylformamide ≤ 880 ppm, in accordance with ICH Q3C Option 1 limits.
    Typical certificate-of-analysis parameters for a production batch released under argon
    ParameterMethodSpecification
    Assay (HPLC, anhydrous basis)USP <621>98.0–102.0%
    Enantiomeric excessChiral HPLC (IA-3)99.0%
    Free thiol (Ellman’s)UV 412 nm0.95–1.05 equiv
    Water (KF)USP <921>0.5% w/w
    Residual PdICP-OES10 ppm
    AppearanceVisualPale-yellow amorphous solid
    Storage under inert atmosphere is mandatory: exposure of the lyophilized solid to ambient air (21% O₂, 50% RH) for 72 hours at 22°C results in disulfide dimer formation exceeding 8% by HPLC. Long-term stability data generated over 24 months at −20 ± 5°C in amber glass vials under argon confirm ≤ 0.6% degradation per annum. A distinct attribute of this building block is the orthogonal reactivity of the 4-nitrobenzyloxycarbonyl (pNZ) protecting group. Unlike the 9-fluorenylmethoxycarbonyl (Fmoc) group, which undergoes β-elimination under piperidine or 4-methylpiperidine treatment, the pNZ moiety is cleaved under mildly acidic, photolytic, or hydrogenolytic conditions. For instance, irradiation at 365 nm (UVP CL-1000 crosslinker, 8 × 8 W tubes) in methanol containing 1% acetic acid removes the pNZ cap within 45 minutes, leaving the concurrent tert-butyl ester and trityl-protected cysteine residues intact—a selectivity window frequently exploited in the assembly of cyclic peptides on 2-chlorotrityl chloride resin.

    Differentiating Structural Features from Analogous Mercaptoproline Derivatives

    Comparison with the (2R,4R) enantiomer illustrates the predictable but operationally critical role of absolute configuration in peptide backbone preorganization. The (2S,4S) diastereomer enforces a cis relationship between the C-4 sulfhydryl and the C-2 urea-substituted carbonyl, yielding a pyrrolidine ring torsion angle χ1 of approximately −28° (X-ray crystallography, Mo Kα radiation, 100 K) versus +31° for the (2R,4R) isomer. In β-turn mimetic design, the (2S,4S) scaffold reproducibly templates a type-VI turn when incorporated at the i+1 position of a tetrapeptide sequence, whereas the (2R,4R) analog destabilizes the turn by 2.3 kcal/mol as measured by CD-monitored thermal unfolding of model 15-mer peptides at 222 nm. Commercially available N-Boc-4-mercapto-L-proline (CAS 87440-56-0) shares the 4-mercaptopyrrolidine core but lacks the N-terminal urea linkage and the 3-carboxyphenyl substituent. Reductive alkylation of the free N-terminus with 4-nitrobenzyl chloride in the presence of N,N-diisopropylethylamine (DIEA) is a documented route to the subject compound, yet direct purchase of the finished (2S,4S) pNZ derivative eliminates a protection step that, when executed at 20-L scale in a Büchi Glas Uster reactor, occasionally suffers from over-alkylation (> 15% N,N-dialkylated impurity) unless the pH is maintained strictly between 7.8 and 8.2 via controlled DIEA addition. This process nuance drives a practical preference for pre-assembled material in medicinal chemistry laboratories that use automated peptide synthesizers (e.g., CEM Liberty Blue 2.0) operating under nitrogen blanket. The incorporation of the 3-carboxyphenyl urea, rather than a simpler acetyl or benzyl carbamate cap, provides a UV-dense chromophore (λmax 272 nm, ε ≈ 14,500 M⁻¹cm⁻¹ in methanol) that facilitates preparative HPLC monitoring without requiring post-column derivatization. Additionally, the free carboxylic acid on the aryl ring enhances aqueous solubility under mildly basic conditions (≥ 0.8 mg/mL in 50 mM ammonium bicarbonate buffer, pH 8.0), a property absent in the corresponding methyl ester or benzyl ester analogs that typically precipitate at concentrations above 0.1 mg/mL in the same medium. When the mercaptan is engaged in thioester-mediated native chemical ligation (NCL), the 4-nitrobenzyl group remains intact if the ligation buffer is kept at pH 6.8–7.0. This tolerance allows one-pot desulfurization without premature deprotection, a sequence that fails with the corresponding Fmoc-protected mercaptoproline owing to Fmoc fragmentation under the standard TCEP/MESNa conditions at 37°C. Unprotected thiol handling on the production floor requires specific attitudinal protocols. At the 3,000-L scale within a Class 100,000 cleanroom, the product is dispensed into double polyethylene bags evacuated to −0.08 MPa and heat-sealed under a nitrogen stream sparged through a 0.22-µm PTFE filter. Operators are advised to wear silver-lined static-dissipative gloves not because of toxicity—acute oral toxicity (rat, LD₅₀) is > 2,000 mg/kg by OECD 423—but to prevent triboelectric charging that can oxidize the thiol to disulfide during powder transfer through non-conductive polypropylene funnels.

    Harnessing Thiol-Nucleophilicity in Peptide Macrocyclization

    The privileged status of this synthon in constrained peptide synthesis stems from the orthogonal pairing of the C-4 thiol with electrophilic handles installed on the elongating peptide chain. A validated procedure for on-resin head-to-side-chain cyclization on Rink amide AM resin (0.52 mmol/g loading) involves coupling Fmoc-Cys(Trt)-OH, followed by Fmoc removal with 20% piperidine in DMF, and subsequent acylation with the (2S,4S)-1-(4-nitrobenzyl)-4-mercaptopyrrolidine-2-carboxylic acid precursor (after activation with HATU/DIEA in DMF). After linear assembly, the trityl group is cleaved with 2% TFA/5% triisopropylsilane in dichloromethane (5 × 2 min), and the deprotected thiol is oxidized to form a disulfide bridge using 50 mM iodine in DMF for 45 minutes. The pNZ group remains stable during this oxidation, an advantage over Alloc-protected analogs that undergo partial reduction in the presence of adventitious triarylphosphine scavengers. For disulfide-free cyclizations via thioether bond formation, the mercaptan is alkylated with a bromoacetylated N-terminus in the presence of 1.5 equivalents of N-methylmorpholine in DMF. The reaction reaches > 95% conversion within 20 minutes as monitored by LC-MS (Waters ACQUITY QDa, ESI positive mode). Cyclic purity of the crude product, isolated by precipitation from cold diethyl ether, typically exceeds 85% by reverse-phase HPLC before preparative purification. The 3-carboxyphenyl substituent, often an underappreciated moiety, has been utilized in fragment-based screening campaigns where surface plasmon resonance (Biacore T200, CMS chip, HBS-EP+ running buffer) detected a KD of 4.2 µM for the isolated building block against the SH2 domain of STAT3—a weak but ligand-efficient starting point for medicinal chemistry optimization. Although this observation does not constitute a therapeutic claim, it illustrates how the building block itself can serve as a probe fragment in biophysical assays, a function not shared by simpler acetyl- or methyl carbamate-protected mercaptoprolines that lack the extended aromatic urea surface. In a variation of solid-phase peptide synthesis conducted on a Syro II parallel synthesizer (Biotage), the compound has been directly loaded onto 2-chlorotrityl chloride resin via its free carboxyl group using 4 equivalents of DIEA in dry DCM. A loading of 0.48 mmol/g was achieved after 2 hours, confirmed by Fmoc release spectrophotometry at 301 nm. This direct anchoring strategy bypasses the need for preformed symmetrical anhydrides and reduces diketopiperazine formation when the subsequent amino acid is a glycine derivative—a documented risk when using pNZ-protected proline analogs at elevated temperatures (> 55°C) during microwave-assisted coupling. Incompatibilities must be strictly observed. The combination of the free thiol with Pd/C catalyst under hydrogen atmosphere at 1 atm results in rapid catalyst poisoning and incomplete pNZ deprotection; transfer hydrogenation with 1,4-cyclohexadiene and 10% Pd/C is a documented safer alternative, though it requires extended reaction times (16–24 hours) and produces benzene as a byproduct. Additionally, exposure to amines stronger than triethylamine (pKa conjugate acid 10.75) in the presence of trace oxygen leads to yellow discoloration and disulfide formation; basification for solubility adjustment should employ N-methylmorpholine or collidine buffers.

    Process engineering records from a campaign at the 250-g scale highlight a viscosity-induced mixing failure when the dissolved crude (in 3 L of 95:5 DCM/methanol) was loaded onto a Büchi Pure C-850 FlashPrep cartridge packed with 500 g of silica (40–63 µm). The feed solution, at 22°C, exhibited a dynamic viscosity of 4.8 mPa·s—exceeding the pump’s rated handling limit of 3.0 mPa·s for the standard PTFE piston seals. Dilution to 6 L with DCM reduced viscosity to 1.9 mPa·s and restored flow uniformity. This observation, while specific to a particular flash chromatography configuration, underscores the necessity of pre-filtering the feed through a 10-µm polyethylene frit and verifying viscosity when scaling normal-phase purifications of this molecule. Quantitative nuclear magnetic resonance (qNMR, Bruker AVANCE III HD 600 MHz, DMSO‑d₆, maleic acid internal standard) has been cross-validated against HPLC area percent and routinely yields assay values within ±0.4% of the chromatographic result, reinforcing confidence in the purity when the batch is used as a reference standard for bioavailability-enhancing prodrug constructs that incorporate a 4-mercaptoproline scaffold. The decision between this (2S,4S) derivative and its (2R,4S) diastereomer (a cis-fused bicyclic alternative) often correlates with the required dihedral angle in the target macrocycle. Molecular dynamics simulations (Amber 20, ff14SB force field, TIP3P water, 100 ns trajectory) of a 14-membered model ring predict that the trans-configured (2S,4S) thiol lowers the ring-strain energy by 3.7 kcal/mol compared to the cis-configured (2R,4S) variant, due to more favorable pre-organization of the amide bond exo to the pyrrolidine ring.